This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / BioArctic Q1 2026 Report Presentation
Business earnings call

BioArctic Q1 2026 Report Presentation

Analysis based on 7 articles · First reported May 13, 2026 · Last updated May 13, 2026

Sentiment
0
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market will be impacted by the release of BioArctic's first quarter report, which will provide financial performance and updates on its neurodegenerative disease treatments. Investors and analysts will closely monitor the presentation by Gunilla Osswald and Anders Martin-Löf for insights into the company's future outlook.

Biotechnology Pharmaceuticals
Event Summary

BioArctic will publish its first quarter report for January - March 2026 on May 20, 2026, at 8:00 a.m. CET. In conjunction with the report, BioArctic is inviting investors, analysts, and media to a webcast and teleconference on May 20, at 9:30 a.m. CET. Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, along with colleagues, will present and comment on the report, followed by a Q&A session. BioArctic is a Swedish biopharma company focused on treatments for neurodegenerative diseases, known for Leqembi, developed with Eisai. BioArctic's B share is listed on Nasdaq Stockholm Large Cap.

Entities Involved
per
Gunilla Osswald
Gunilla Osswald, CEO of BioArctic, will present and comment on the first quarter report during the webcast and teleconference.
Importance 70.0 Sentiment 0.0
per
Anders Martin-Löf
Anders Martin-Löf, CFO of BioArctic, will present and comment on the first quarter report during the webcast and teleconference.
Importance 70.0 Sentiment 0.0
exch
Nasdaq Stockholm
Importance 0.0 Sentiment 0.0
stock
Eisai
Importance 0.0 Sentiment 0.0
stock
BioArctic
Importance 0 Sentiment 0
Relationships
Eisai licensee ↔ BioArctic Eisai holds the license to clinically develop and commercialize BioArctic's Alzheimer's drug Leqembi globally, paying ro
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.